FP-01.1-Adjuvant + TIV

FP-01.1-Adjuvant + TIV is a combination vaccine candidate designed to enhance immune protection against influenza A by combining two components: - **FP-01.1** is a novel synthetic peptide-based pan-influenza A vaccine composed of six fluorocarbon-modified 35-mer peptides, each containing multiple CD4+ and CD8+ T-cell epitopes derived from internal proteins of influenza A virus[1][6]. These peptides are engineered to induce broad cellular immunity across diverse populations by stimulating both helper and cytotoxic T cell responses that can cross-recognize divergent influenza strains[1][6]. - **TIV** refers to the trivalent inactivated influenza vaccine, which contains purified hemagglutinin (HA) and neuraminidase (NA) proteins from three selected seasonal influenza virus strains (typically two type A subtypes and one type B)[5][6]. The addition of an adjuvant enhances the immunogenicity of both components. The combination aims to provide broader protection than standard vaccines by inducing robust humoral (antibody-mediated) and cellular immune responses.